Usefulness of Mean Platelet Volume and Neutrophil-To-Lymphocyte Ratio for Development of Atrial Fibrillation After Acute Myocardial Infarction

Yıl 2019, Cilt: 10 Sayı: 3, 278 - 283, 20.09.2019

Hasan Aydın Baş , Ali Bağcı , Fatih Aksoy

https://doi.org/10.22312/sdusbed.543444

Cited By: 3

Öz

Amaç:
Atriyal fibrilasyon (AF), ST yükselmiş miyokard infarktüsünü (STEMI) takiben en
sık görülen supraventriküler aritmidir. Ortalama trombosit hacmi (MPV)
trombosit aktivasyonunun ve fonksiyonunun bir göstergesidir. Ortalama trombosit
hacmi, gelecekteki inme ve miyokard enfarktüsü için bağımsız bir risk faktörü
olarak belirlenmiştir. Nötrofil / lenfosit oranı (NLR) tespiti, inflamatuar
durumu değerlendirmek için hızlı ve basit bir yöntem olup son zamanlarda kardiyovasküler
risk ve AF için bir ön gördürücü olarak saptanmıştır.  Bu çalışmanın amacı, STEMI sonrası AF
gelişiminde NLR ve MPV düzeyleri arasındaki olası bir ilişkiyi
değerlendirmektir.

Yöntem: Bu
prospektif çalışmaya, koroner bakım ünitesine başvuran, akut STEMI' li 743
hasta dahil edildi. Hastalar AF olan ve olmayan iki gruba ayrıldı. AF gelişimin
ön gördürücüleri çok değişkenli regresyon analizi ile belirlendi.

Bulgular: STEMI
ile başvuran toplam 743 hastanın 82 sinde (%11) AF gelişti. Ortalama trombosit
hacmi ve NLR, AF' gelişen hastalarda AF gelişmeyen hastalara göre anlamlı
derecede yüksekti (sırasıyla p <0,001). Çok değişkenli regresyon analizi sonuçları,
yaş [Odds ratio (OR)=1,03; %95 Güven Aralığı (GA)=1,01-1,05; p=0,001),
ejeksiyon fraksiyonu (OR=0,95; %95 GA = 0,93-0,98; p <0,001), MPV (OR=1,738;
% 95 GA = 1,29-2,33; p<0,001), NLR (OR=1,08; %95, GA=1,01-1,15; p=0,025) ve
hastane öncesi anjiyotensinojen dönüştürücü enzim blokerleri kullanımı
(OR=3.04; % 95 GA=1,22-7,54; p = 0,017), STEMI hastalarında AF gelişimi ile
ilişkiliydi.

Sonuç: Bu
çalışma, MPV ve NLR' nin STEMI hastalarda AF gelişimi ile ilişkili olduğunu ve
AF' nin diğer bağımsız ön gördürücülerinin ise yaş ve ejeksiyon fraksiyonunu
olduğunu göstermiştir.

Anahtar Kelimeler

Miyokard infarktüsü, atriyal fibrilasyon, ortalama trombosit hacmi, nötrofil lenfosit oranı

Usefulness of mean platelet volume and neutrophil-to-lymphocyte ratio for development of atrial fibrillation after acute myocardial infarction

Öz

Objective: Atrial fibrillation (AF) is the most
common supraventricular arrhythmia following ST elevated myocardial infarction
(STEMI). Mean platelet volume
(MPV) is an indicator of platelet activation and function. Mean platelet volume has been
identified as an independent risk factor for future stroke and myocardial
infarction. The neutrophil-to-lymphocyte ratio (NLR), fast and easy method for detecting
inflammatory status, have been recently explored as a predictor for
cardiovascular risk and AF. The aim of the present study was to evaluate a
possible relationship between NLR and MPV levels on development of AF
after STEMI.

Methods: This prospective study consisted of
743 patients with acute STEMI who were admitted to coronary care unit. Patients
were divided into two groups, patients with and without AF. Predictors of AF
were determined by multivariate regression analysis.

Results: From a total of 743 patients
presenting with STEMI, 82 (11%) developed AF. Mean platelet volume and NLR was significantly
higher in patients with AF compared to without AF (p<0.001, respectively).
Multivariate regression analysis results showed that, age [Odds Ratio
(OR)=1.03; 95% Confidence Interval (CI)=1.01-1.05; p=0.001), ejection fraction
(OR=0.95; 95% CI=0.93-0.98; p<0,001), MPV (OR=1.738; 95% CI=1.29-2.33;
p<0.001), NLR (OR=1.08; 95% CI=1.01-1.15; p=0,025) and previous
angiotensinogen converting enzyme blockers (OR=3.04; 95% CI=1.22-7.54; p=0,017)
using were associated with development of AF in patients with acute STEMI.

Conclusions: This study showed that, MPV and NLR
were associated with the development of AF in patients presenting STEMI, other
independent predictors of AF included age, and ejection fraction.

Anahtar Kelimeler

Myocardial infarction, atrial fibrillation, mean platelet volume, neutrophil-to-lymphocyte ratio

Kaynakça

• 1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European heart journal. 2010;31(19):2369-429.
• 2. Asanin M, Perunicic J, Mrdovic I, Matic M, Vujisic-Tesic B, Arandjelovic A, et al. Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction. European journal of heart failure. 2005;7(4):671-6.
• 3. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation. 2000;101(9):969-74.
• 4. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002;13(5-6):301-6.
• 5. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. European heart journal. 2001;22(17):1561-71.
• 6. Ha SI, Choi DH, Ki YJ, Yang JS, Park G, Chung JW, et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets. 2011;22(6):408-14.
• 7. Mathur A, Robinson MS, Cotton J, Martin JF, Erusalimsky JD. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thrombosis and haemostasis. 2001;85(6):989-94.
• 8. Colkesen Y, Acil T, Abayli B, Yigit F, Katircibasi T, Kocum T, et al. Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2008;19(5):411-4.
• 9. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. International journal of clinical practice. 2005;59(8):981-2.
• 10. Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. The American journal of cardiology. 2010;106(4):470-6.
• 11. Corriere T, Di Marca S, Cataudella E, Pulvirenti A, Alaimo S, Stancanelli B, et al. Neutrophil-to-Lymphocyte Ratio is a strong predictor of atherosclerotic carotid plaques in older adults. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2018;28(1):23-7.
• 12. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. European heart journal. 2009;30(9):1038-45.
• 13. Saczynski JS, McManus D, Zhou Z, Spencer F, Yarzebski J, Lessard D, et al. Trends in atrial fibrillation complicating acute myocardial infarction. The American journal of cardiology. 2009;104(2):169-74.
• 14. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, et al. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. Cardiac electrophysiology review. 2003;7(3):201-7.
• 15. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Journal of the American College of Cardiology. 1997;30(2):406-13.
• 16. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart. 2001;86(5):527-32.
• 17. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338(8780):1409-11.
• 18. Dogan A, Aksoy F, Icli A, Arslan A, Varol E, Uysal BA, et al. Mean platelet volume is associated with culprit lesion severity and cardiac events in acute coronary syndromes without ST elevation. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2012;23(4):324-30.
• 19. Unal EU, Ozen A, Kocabeyoglu S, Durukan AB, Tak S, Songur M, et al. Mean platelet volume may predict early clinical outcome after coronary artery bypass grafting. Journal of cardiothoracic surgery. 2013;8(1):91.
• 20. Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG. High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. Journal of thrombosis and haemostasis : JTH. 2011;9(1):49-56.
• 21. Erdogan D, Tayyar S, Icli A, Uysal BA, Varol E, Ozaydin M, et al. Elevated mean platelet volume is associated with impaired coronary microvascular function in patients with idiopathic dilated cardiomyopathy. Platelets. 2012;23(3):177-83.
• 22. Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. Journal of the American College of Cardiology. 2007;49(19):1957-64.
• 23. Erdem K, Ayhan S, Ozturk S, Bugra O, Bozoglan O, Dursin H, et al. Usefulness of the mean platelet volume for predicting new-onset atrial fibrillation after isolated coronary artery bypass grafting. Platelets. 2013.
• 24. Karatas MB, Canga Y, Ipek G, Ozcan KS, Gungor B, Durmus G, et al. Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention. Coronary artery disease. 2016;27(2):128-34.
• 25. Arslan A, Ozaydin M, Aksoy F, Arslan B, Bas HAB, Erdogan D, et al. Association between the use of renin-angiotensin system blockers and development of in-hospital atrial fibrillation in patients with ST-segment elevation myocardial infarction. Medicina. 2016;52(2):104-9.